Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.
2152301
-1-
METHOD OF AMPLIFICATION USING INTERMEDIATE
RENATURATION STEP
gield of the Invention
This invention relates to a rapid - ~
preferential coamplification of two or more double-
stranded nucleic acids whereby a renaturation step is
included among multiple amplification cycles.
Backaround of the Invention
Detection of nucleic acids has grown in
recent years as a means for early detection of genomic
features, infectious agents and various organisms which
are present in very small quantities in a human or
animal test specimen. Detection procedures are
normally based on the concept of complementarity
whereby.two DNA strands are bound together by hydrogen
bonds and other forces between complementary
nucleotides (which are known as nucleotide pairs).
A DNA molecule is normally quite stable, but
the strands can be separated or denatured by certain
conditions, such as heating. The denatured strands
will reassociate only with another strand having a
complementary sequence of nucleotides.
Much research has been carried out to find
ways to detect only a few molecules of a DNA. Various
procedures are known and have been used for almost a
decade to amplify or greatly multiple the number of
nucleic acids in a specimen for detection. Such
amplification techniques include polymerase chain
reaction (PCR), ligase chain reaction (LCR) and others
which are less developed.
PCR is the most well known and involves the
hybridization of primers to the strands of a target
nucleic acid in the presence of a DNA polymerization
agent and deoxyribonucleotide triphosphates under
appropriate conditions. The result is the formation of
2f5230i
-2-
primer extension products throughout several cycles and
exponential multiplication of the number of original
target strands. Further details about PCR can be
obtained by consulting US-A-4,683,195 (Mullis-et al),
US-A-4,683,202 (Mullis) and US-A-4,965,188 (Mullis et
al).
Human and animal specimens contain many
different nucleic acids, some of which are endogenous
(or natural) to the person or animal, and others which
are produced because of some abnormal condition, such
as from the presence of an infectious agent or an
oncogenic condition. Such nucleic acids are usually
present in very low concentrations compared to
endogenous nucleic acids. They are sometimes referred
to as "low copy number" nucleic acids. By comparison,
the endogenous nucleic acids are usually present in
high concentrations and may be referred to as "high
copy number" nucleic acids. One such example is human
P-globin DNA.
Frequently, in using PCR, two or more nucleic
acids present in the specimen are amplified at the same
time in the same reaction container. This is
identified herein as "coamplification". This process
requires that primers for each nucleic acid to be
amplified must be simultaneously present in the
container.
When both low and high copy target nucleic
acids are amplified in such situations, amplification
of the low copy target nucleic acid is often inhibited.
This is due to the saturation of the amplifying enzyme
(such as DNA polymerase) by the high copy target
nucleic acid during the later cycles of amplification.
False negative results for the presence of the low copy
target nucleic acid would be likely, with possibly
serious.consequences.
_ 2152301
-3-
Various solutions to the problem have been
proposed for PCR, including adjusting the
concentrations of the primers, utilizing primer sets
with specific melting temperatures (Tm's), or_
combinations thereof. Adjusting the primer ratios has
been referred in the art as "primer biasing" the PCR
yield, and requires a decrease in the concentration of
primers for the high copy target nucleic acid. Only
modest control of the process is achieved with this
approach.
Another approach to coamplification has been
to adjust the temperature of annealing in PCR such that
the primers for the high copy target nucleic acid
anneal to a lesser extent than those for the low copy
target nucleic acid. This approach also has a problem.
The Tm difference between primer pairs must be
relatively large before good modulation of PCR can be
exerted on the differential yields for the high and low
copy nucleic acids. Exact Tm's cannot be calculated
(although they can be estimated), and thus they must be
measured. This requires a high degree of effort, and
considerable tedium.
All of these approaches to modulate
coamplification require that the high and low copy
target nucleic acid sequences be known.
Alternatively, adding time to the priming or
extension steps in PCR in later cycles can minimize the
DNA polymerase saturation by the high copy target
nucleic acid and increase amplification efficiency.
However, this solution has limited utility in
situations where many nucleic acids which are present
in varying concentrations, are being amplified
simultaneously.
It would be desirable to achieve rapid and
efficient amplification of one or more low copy target
_2152301
-4-
nucleic acids when coamplified in the preser.ce of one
or more high copy target nucleic acids.
Sumrnarv of the Invention
The problems noted above have been overcome
with a method for the coamplification of two or more
target nucleic acids, the method comprising:
I) at least 15 primary amplification cycles of
from about 20 to about 360 seconds each, each cycle
comprising the sequential steps of:
A) heating a reaction mixture of two or
more target nucleic acids or their primer extension
products, at least one of the target nucleic acids
being a low copy target nucleic acid, and at least one
other of the target nucleic acids being a high copy
target nucleic acid which is suspected of being present
at at least about 1000 times the concentration of the
low copy nucleic acid,
the heating being carried out at a first
temperature, T1, of from about 85 to about 100 C for
denaturation of the strands of the high anc low copy
target nucleic acids or their primer extension
products,
B) priming the denatured strands with a set
of primers specific to and hybridizable with opposing
strands of each target nucleic acid to be amplified, by
cooling to a second temperature, T2, which is defined
as:
(TmH - 15) C < T2 < (TmH + 5) C
wherein TmH is the melting temperature of the primers
for the high copy target nucleic acid,
C) either as a continuation of step B) or
in a different step, forming primer extension products
in a reaction mixture of PCR reagents, by incubation at
a third temperature, T3, which is defined as:
(TmH -_15) C < T3 < (TmH + 15) C,
2152301
.~ -
-5-
provided that when priming and primer extension
products formation are carried out in the same step, '2
and T3 are the same, and
II) at least 5 secondary amplification cycles of
from about 20 to about 360 seconds each, each cycle
comprising repeating steps A) through C) identified
above sequentially,
provided that between steps A) and B) of each
secondary amplification cycle, the reaction mixture is
cooled to and maintained at a fourth temperature, T4,
which is defined as:
(TMH + S ) C < T4 < TpH
wherein TPH is the melting temperature of the double
strands of the high copy target nucleic acid, for from
about 15 to about 120 seconds.
The present invention provides a very rapid
and efficient method for preferentially amplifying and
detecting a low copy target nucleic acid, especially in
the presence of high copy target nucleic acids which
potentially obscure the signal for the low copy targe:.
nucleic acid. Thus, inhibition of the low copy targe:.
nucleic acid amplification by the high copy target
nucleic acid, is reduced.
These advantages are achieved by including a
renaturation step within the later cycles of the
amplification process so that after a certain number of
amplification cycles (identified herein as "primary"
cycles), the amplified products are renatured or
hybridized for a brief period of time after each
denaturation step in subsequent cycles (identified
herein as "secondary~ cycles). The renaturation step
is carried out at a temperature at which the
complementary strands of the denatured products can
readily renature or hybridize. However, the
temperature is maintained above that at which the hich
CA 02152301 2005-08-23
-6-
copy target nucleic acid primers efficiently anneal to the complementary
strands of
the denatured amplified product. A sufficient amount of time is allowed for
renaturation, thereby reducing the effective concentration of high copy target
nucleic acid available for priming and subsequent amplification. This allows
more
efficient amplification of the low copy target nucleic acid in subsequent
cycles as
more DNA polymerase is available.
Detailed Description of the Invention
The general principles and conditions for amplification and
detection of nucleic acids using polymerase chain reaction are quite well
known,
the details of which are provided in numerous references including US-A-
4,683,195, US-A-4,683,202 and US-A-4,965,188 (noted above). Thus, in view of
the teaching in the art and the specific teaching provided herein, a worker
skilled in
the art should have no difficulty in practicing the present invention by
making the
adjustments taught herein to coamplify two or more nucleic acids, one of which
is
a low copy target nucleic acid.
Other amplification procedures which can be used in the practice of
this invention include ligase chain reaction as described, for example, in EP-
A-0
320 308 (published December, 1987) and EP-A-0 439 182 (published January,
1990), and any other known amplification procedure which includes a product
denaturation step. Thus, the teaching provided herein would allow one skilled
in
the art to adapt the renaturation modification shown for PCR to these other
known
amplification procedures. The remainder of this disclosure is directed to
practicing
the invention using PCR for illustrative purposes.
_ 2152301
_7_
The present invention is directed to the
amplification and detection of one or more specific
nucleic acid sequences present in one or more low copy
target nucleic acids in a test specimen simultaneously
with the amplification of one or more nucleic acid
sequences present in one or more high copy target
nucleic acids. Generally, a low copy target nucleic
acid is present in a specimen in an amount of less than
about 10-16 molar, however, the amount can be greater
if the high copy nucleic acids are present in much
higher amounts, for example, at least 1000 times
greater in concentration. High copy target nucleic
acids are those generally associated with single copy
genes while low copy target nucleic acids are generally
those associated with infectious agents, cancers and
other pathological conditions in a human or animal.
In addition, the high copy target nucleic
acid can be used as a "positive control" in an assay.
By modulating the efficiency of PCR of the high copy
target nucleic acid, the positive control can be
detectable only if PCR was carried out efficiently,
thereby reducing the probability of false negatives.
In such instances, the high copy target nucleic acid
may be present at 10 or more times the concentration of
the low copy target nucleic acid.
Test specimens can include cellular or viral
material, hair, body fluids or other materials
containing genetic DNA or RNA which can be detected.
Target nucleic acids can be obtained from various
sources including plasmids, and naturally occurring DNA
or RNA from any source (such as bacteria, yeast,
viruses, plants, higher animals or humans). It may be
extracted from various tissues including blood,
peripheral blood mononuclear cells (PBMC), other tissue
materials or other sources known in the art using known
_2152301
-8-
procedures. The present invention is particularly
useful for the coamplification and detection of nucleic
acid sequences found in genomic DNA, bacterial DNA,
fungal DNA, viral RNA, or DNA or RNA found in-bacterial
or viral infected cells. In addition, nucleic acid
sequences associated with cancer markers are
amplifiable and detectable using the present invention.
Bacteria which can be detected include, but
are not limited to, bacteria found in human blood,
Salmonella species, Chlamydia species, Gonococcal
species, Shigella species and Mycobacterium species.
Viruses which are detectable include, but are not
limited to, herpes simplex viruses, Epstein Barr virus,
human cytomegalovirus, human papilloma virus, hepatitis
viruses and retroviruses such as HTLV-I, HTLV-II, HIV-I
and HIV-II. Protozoan parasites, yeasts and molds are
also detectable. Other detectable species would be
readily apparent to one skilled in the art. The
invention is particularly useful for the detection of
the presence of DNA associated with a-retroviral DNA
(HIV-I or HIV-II) or a Mycobacterium species. Most
preferably, it is used to detect DNA associated with
HIV-I.
A"PCR reagent" refers to any of the reagents
considered essential to PCR, namely a set of primers
for the opposing strands of each target nucleic acid, a
DNA polymerase, a DNA polymerase cofactor, and two or
more deoxyribonucleoside-5'-triphosphates (dNTP's).
The term "primer" refers to an
oligonucleotide, whether naturally occurring or
synthetically produced, which is capable of acting as a
point of initiation of synthesis when placed under
conditions in which synthesis of a primer extension
product complementary to a nucleic acid strand (that
is, template) is induced. Such conditions include the
_2152301
-9-
presence of the other PCR reagents, and suitable
temperature and pH. The primer must be long enough to
prime the synthesis of extension products in the
presence of the DNA polymerase. The exact size of each
primer will vary depending upon the use contemplated,
the complexity of the targeted sequence, reaction
temperature and the source of the primer. Generally,
the primers used in this invention will have from 10 to
60 nucleotides.
Primers can be obtained from a number of
sources or prepared using known techniques and
equipment, including for example, an ABI DNA
Synthesizer (available from Applied Biosystems) or a
Biosearch 8600 Series or 8800 Series Synthesizer
(available from Milligen-Biosearch, Inc.) and known
methods for their use (for example as described in US-
A-4,965,188, noted above). Naturally occurring primers
isolated from biological sources are also useful (such
as restriction endonuclease digests). A set of at
least two primers is generally used for each target
nucleic acid. Thus, a plurality of sets of primers can
be used simultaneously to amplify a plurality of target
nucleic acids. In addition, a set of primers can
include a mixture of primers for a given target nucleic
acid.
DNA polymerases are well known as enzymes
which will esterify and add deoxynucleoside
monophosphate molecules to the 3'-hydroxy end of the
primer by a phosphodiester linkage to the primer, with
synthesis being template directed. Useful DNA
polymerases include for example, E. coli DNA polymerase
I, T4 DNA polymerase, Klenow polymerase, reverse
transcriptase and others known in the art.
The DNA polymerase is preferably
"thermostable", meaning that it is generally stable at
CA 02152301 2005-08-23
-10-
the high temperatures used for denaturation of DNA strands. More particularly,
the
thermostable DNA polymerases are not substantially inactivated at the high
temperatures used in PCR. Such temperatures will vary depending upon a number
of reaction conditions, including pH, salt concentration, and other conditions
known in the art.
A number of thermostable DNA polymerases have been reported in
the art, including those mentioned in detail in US-A-4,965,188 (noted above)
and
US-A-4,889,818 (Gelfand et al). Particularly useful polymerases are those
obtained
from various Thermus bacterial species, such as Thermus aquaticus, Thermus
filiformis, Thermus flavus or Thermus thermophilus. Other useful thermostable
polymerases are obtained from a variety of other microbial sources including
Thermococcus literalis, Pyrococcus furiosus, Thermotoga sp. and those
described
in WO-A-89/06691 (published July 27, 1989). Some useful enzymes are
commercially available. A number of techniques are known for isolating
naturally-
occurring polymerases from organisms.Cloning and other synthetic techniques
for
preparing polymerases using recombinant techniques are also known from the art
cited above, including the Gelfand et al patent.
A DNA polymerase cofactor refers to a nonprotein compound on
which the enzyme depends for activity. A number of such materials are known in
the art, including manganese and magnesium salts. Useful cofactors include,
but
are not limited to, manganese and magnesium chlorides, sulfates, acetates and
fatty
acid salts. The chlorides, sulfates and acetates are preferred, and the
magnesium
chlorides and sulfates are most preferred.
CA 02152301 2005-08-23
-11-
Also needed for PCR are two or more deoxyribonucleoside-5'-
triphosphates, such as dATP, dCTP, dGTP, dTTP and dUTP. Analogues such as
dITP and 7-deaza-dGTP are also useful. Preferably, the four common
triphosphates (dATP, dCTP, dGTP and dTTP) are used in PCR.
Also useful in the practice of the invention is an antibody specific to
the DNA polymerase, which antibody inhibits its enzymatic activity at
temperatures below about 50 C, but which antibody is deactivated at higher
temperatures. Representative monoclonal antibodies having these properties are
described in U.S. Patent No. 5,338,671 (filed October 7, 1992 by Scalice et
al).
Antibody fragments can be used in place of the whole molecule.
The PCR reagents described herein are provided and used in PCR in
suitable concentrations to provide amplification of the target nucleic acid.
The
minimal amounts of DNA polymerase is generally at least about 1 unit/100 l of
solution, with from about 4 to about 25 units/100 gl being preferred. A "unit"
is
defined herein as the amount of enzyme activity required to incorporate 10
nmoles
of total nucleotides (dNTP's) into an extending nucleic acid chain in 30
minutes at
74 C. The concentration of each primer is at least about 0.075 gmolar with
from
about 0.1 to about 2 molar being preferred. The primers can be present in the
same or different amounts. Preferably, the primers of each set of primers for
each
target nucleic acid are initially present in the reaction mixture in the same
amount.
The cofactor is generally present in an amount of from about 1 to about 15
mmolar, and each dNTP is generally present at from about 0.15 to about 3.5
mmolar in the reaction mixture.
2152301
-12-
The PCR reagents can be supplied
individually, or in a buffered solution having a pH in
the range of from about 7 to about 9 using any suitable
buffer. Thus, a reaction mixture for PCR can-contain a
set of primers for a low copy target nucleic acid, a
set of primers for a high copy target nucleic acid,
suitable dNTP's, a thermostable DNA polymerase, a
cofactor for the DNA polymerase, and any other addenda
that one skilled in the art would consider useful in
the amplification or eventual detection of the target
nucleic acids.
A target nucleic acid can be obtained from
any of a variety of sources as noted above. Generally,
it must be extracted in some manner to make it
available for contact with the primers and other
reaction materials. This usually means removing
unwanted proteins and cellular matter from the specimen
in a suitable manner. Various procedures are known in
the art, including those described by Laure et al in
The Lancet, pp. 538-540 (Sept. 3, 1988), Maniatis et
al, Molecular Clonina: A Laboratory Manual, pp. 280-281
(1982), Gross-Belland et al in Eur.J.Biochem., U, 32
(1973) and US-A-4,965,188 (noted above). Extraction of
DNA from whole blood or components thereof are
described, for example, in EP-A-0 393 744 (published
October 24, 1990), Bell et al, Proc. Nat1. Acad. Sci.
USA, Z$(9), pp. 5759-5763 (1981), Saiki et al,
Bio/Technology, 3-, pp. 1008-1012 (1985) and US-A-
5,231,015 (Cummins et al). The particular extraction
procedure is not essential to the practice of the
present invention.
Since the target nucleic acid to be amplified
and detected is usually in double strand form, the two
strands must be separated (that is, denatured) before
priming can take place. This can occur during the
2~5230~
-13-
extraction process, but preferably, it occurs in a
separate step afterwards. Heating to a suitable
temperature (identified as "first temperature" or T1
herein) is a preferred means for denaturation.-
Generally, this first temperature is in the range of
from about 85 to about 100 C for a suitable time, for
example from 1 to about 240 seconds (preferably 1 to
about 40 seconds). This initial denaturation step can
also be included in the first amplification cycle. In
such instances, denaturation may be longer in the first
cycle (for example, up to 240 seconds) whereas later
cycles can have much shorter denaturation steps (for
example, up to 30 seconds).
The denatured strands are then primed with
the appropriate set of primers by cooling the reaction
mixture to a second temperature, T2, which is generally
within the range of from about 55 to about 70 C. It is
desired that cooling is done quickly as possible, but
with presently known equipment, it generally takes
place over a time period of from about 5 to about 40
seconds, and more preferably for from about 5 to about
20 seconds. Preferably, T2 is defined as:
(TMH - 15) C < T2 < (TMH + 5) C
wherein TrnH is the melting temperature of the primers
for the high copy target nucleic acid.
Once the denatured strands are cooled, the
reaction mixture containing the PCR reagents is
incubated at a third temperature, T3, generally for
from 1 to about 120 seconds, and preferably for from 1
to about 80 seconds, to effect formation of primer
extension products. Generally, the third temperature
is defined as:
(TMH - 15) C < T3 < (TMH + 15) C
_2152301
-14-
and is generally within the range of from about 55 to
about 70 C. Preferably, it is within the range of
from about 62 to about 68 C.
in a most preferred embodiment, the-second
and third temperatures are the same and are within the
range of from about 62 to about 68 C. Thus, priming
and primer extension are preferably carried out in the
same step.
Each primer for the high copy target nucleic
acid also has a melting temperature identified herein
as TmH. Usually, the difference between TmL and TmH is
from 0 to about 8 C, and both T2 and T3 are usually
lower than TmL or TmH or equal to either TmL or TmH.
Melting temperature is defined herein as the
temperature at which one-half of a primer is denatured
from a complementary strand (such as the template).
The determination of the melting temperatures can be
accomplished using several standard procedures, based
on ultraviolet hypochromism, for example, by monitoring
the spectrum at 26U nm-as described in Biochemistry-The
Molecular Basis of Cell Structure and Function, 2d
Edition, Lehninger, Worth Publishers, Inc., 1970, pp.
876-7. The various methods of determining melting
temperatures may produce slightly differing values for
the same DNA molecule, but those values should not vary
by more than about 2 or 3 C. Moreover, the difference
between TmL and TmH should not vary within a given
method for determining melting temperatures.
Preferably, the melting temperatures are
calculated using the formula:
Tm ( C) = 67.5 + 0.34(%G + C) - 395/N
wherein G" and "C" represent the number of guanine and
cytosine nucleotides, respectively, and "N" represents
the total number of nucleotides in the oligonucleotide
(that is, the primer). Melting temperature values
_ 2f5~~01
_15-
obtained by this calculation correlate very well with
the values determined empirically at room temperature
using conventional UV hypochromism and a conventional
Hewlett-Packard diode array spectrophotometer-(scanning
rate of about +10C/min.) for a solution of primer in 10
mmolar tris(hydroxymethyl)aminomethane buffer (pH 8.5)
having an ionic strength of at least about 20 mmolar
provided by one or more inorganic or organic salts,
such as magnesium chloride, sodium chloride and others
readily apparent to one skilled in the art. The
amounts of primer and its complement in the solution
used to determine the noted melting temperature formula
were sufficient to provide an optical density of from
about 0.5 to about 1.0 OD units.
Thus, a "primary" amplification cycle
comprises the denaturation, priming (or annealing) and
primer extension steps described above. Generally, at
least 15 of such primary amplification cycles are
carried out in the practice of this invention with the
maximum number of cycles being within the discretion of
the particular user. In most instances, 15 to 35
primary amplification cycles are used in the method
with 25 cycles being preferred. Each primary
amplification cycle is generally from about 20 to about
360 seconds, with a cycle time of from about 30 to
about 120 seconds being preferred and from about 30 to
about 90 seconds being more preferred. However, longer
or shorter cycle times can be used if desired.
After at least 15 primary amplification
cycles as defined above, subsequent or "secondary"
amplification cycles are carried out having the same
steps, except that a renaturation step is included
after each denaturation step and before the priming
step.
_2152301
-16-
Renaturation is accomplished by cooling the
reaction mixture to a fourth temperature, T4, defined
as:
(TMH + 5) C <_ T4 :9 TPH
wherein TPH is the melting temperature of the double
strands of the high copy target nucleic acid being
detected. Generally, T4 is from about 65 to about
90 C. The time needed to reach T4 is as short as
possible, but it may be up to about 45 seconds, and
that temperature can be maintained for from about 15 to
about 100 seconds.
At least 5 secondary amplification cycles are
used in the method with an upper limit being at the
discretion of the user. Preferably, the method
includes from 5 to 20 secondary cycles, and 15 cycles
are most preferred. The time for each secondary cycle
is from about 20 to about 360 seconds. A preferred
cycle time is from about 30 to about 120 seconds.
As used in this application, when used in
reference to time for.a given step, the term "about"
refers to 10% of that time limit. When used in
reference to temperatures, the term "about" refers to
f5 C.
The kinetics of nucleic acid hybridization
reactions, such as renaturation of amplification
products, are linearly related to the concentration of
the nucleic acids being hybridized. Therefore, as the
concentration of amplified product increases for
example, 10 times, the hybridization rate also
increases 10 times (and the t~j for renaturation
decreases 10 times). Assuming a forward rate constant
for hybridization of 5 x 106 molar-1
sec-1, the N would be about 14 seconds at a product
concentration of 10-8 molar, and 140 seconds at a
product concentration 10-9 molar.
CA 02152301 2005-08-23
-17-
Inclusion of a product renaturation step in the later cycles at a
temperature at or below the effective high copy product T. (melting
temperature)
but several degrees above the effective Tm of the primers used in the
amplification
reaction allows for renaturation of amplification products in a concentration
dependent manner. The relatively short renaturation step of the secondary
cycles
does not substantially affect the efficiency of priming of the low copy target
nucleic acid, but will decrease priming of the high copy target nucleic acid.
The amplification method of this invention is preferably conducted
in a continuous, automated manner so that the reaction mixture is temperature
cycled in a controlled manner for a desired number of times. A number of
instruments have been developed for this purpose, as one of ordinary skill in
the art
would know. Preferably, the instrument used will also be programmable for the
renaturation step and the resumption of amplification cycles thereafter.
One such instrument for this purpose is described in some detail in
US-A-4,965,188 and EP-A-0 236,069. Generally, this instrument includes a heat
conducting container for holding a number of reaction tubes containing
reaction
mixture, a means for heating, cooling and temperature maintenance, and a
computing means to generate signals to control the amplification sequence,
changes in temperature and timing.
EP-A-0 402 994 provides details of useful chemical test packs
which can be processed using the instrument described in US-A-5,089,233
(Devaney, Jr. et al). Also described therein are means for heating and cooling
the
test pack at repeated intervals (that is, through cycles) appropriate for the
method
of the present invention.
CA 02152301 2005-08-23
-18-
Further details regarding useful PCR processing equipment can be obtained from
the
considerable literature in the field, and would be readily known by one
skilled in the
art.
Besides chemical test packs described above, the method can be
carried out in other containers such as those described in more detail in US-A-
4,902,624 (Columbus et al), US-A-5,173,260 (Zander et al) and US-A-5,229,297
(Schnipelsky et al), and any other suitable container which is readily
apparent to one
skilled in the art.
Detection of amplified products can be accomplished using any
known procedure, including Southern blotting techniques, as described in US-A-
4,965,188 (noted above), or by use of labeled probes or primers, as is known
in the
art.
Alternatively to the embodiments described above, the amplified
products can be detected using a labeled oligonucleotide which is
complementary to
one of the primer extension products. Procedures for attaching labels to
oligonucleotides are well known. Useful labels include enzymes, ferritin and
other
magnetic particles, radioisotopes, chemiluminescent reagents (for example,
luminol), biotin and various fluorogens and chromogens. Useful enzyme labels
include glucose oxidase, peroxidase and alkaline phosphatase. Substrates and
dye
providing reagents for various labels, such as enzymes, are also known.
In a preferred embodiment, an enzyme label (such as peroxidase) is
used for detection, and a suitable composition for providing a dye or light
emission
is used with that label. For example, particularly useful colorimetric dye
providing
systems are described in US-A-5,024,935 (McClune et al). Detection is then
achieved either using the unaided
-19-
eye, or with suitable spectrophotometers or
luminometers.
It is also possible that one of the primers
of each primer set used in the method is labeled with a
specific binding moiety. This moiety can be the same
or different for various primers, and include any
molecule for which there is a specific binding receptor
which reacts specifically with that moiety. Examples
of specific binding pairs (one of which can be the
label) include, but are not limited to,
streptavidin/biotin, sugar/lectin, antibody/hapten,
antibody/antigen and other readily apparent to one
skilled in the art. The receptor molecule is then
conjugated with a suitable detectable label moiety such
as an enzyme, radioisotope or others described above
for oligonucleotides.
More preferably, one or both primers of each
primer set are labeled with biotin (or an equivalent
derivative thereof), and the amplified product is
detected using a conjugate of streptavidin and an
enzyme, such as horseradish peroxidase.
In heterogeneous detection systems of this
invention, the amplified products are captured on a
water-insoluble substrate of some kind, and the other
materials in the reaction mixture are removed in a
suitable manner, such as by filtration, centrifugation,
washing or another separation technique.
Capture probes can be attached to water-
insoluble supports using known attachment techniques
(including absorption and covalent reactions). One
such technique is described in EP-A-O 439 222
(published September 18, 1991). Other techniques are
described, for example, in US-A-4,713,326 (Dattagupta
et al), US-A-4,914,210 (Levenson et al) and EP-B-O 070
687 (published-January 26, 1983). Useful separation
CA 02152301 2005-08-23
-20-
means include filtration through membranes such as polyamide microporous
membranes commercially available from Pall Corporation.
However, any useful solid support can be used to anchor the capture
probe and eventual hybridization product, including microtiter plates, test
tubes,
beakers, magnetic or polymeric particles, metals, ceramics, and glass wool to
name
a few. Particularly useful materials are magnetic or polymeric particles
having
reactive groups useful for covalently attaching the capture probe. Such
particles are
generally from about 0.001 to about 10 meters. Further details about examples
of
such materials are provided in US-A-4,997,772 (Sutton et al), US-A-5,147,777
(Sutton et al), US-A-5,155,166 (Danielson et al) and US-A-4,795,698 (Owen et
al).
The capture probe can be affixed to a flat support such as a polymeric
film, membranes, filter papers, or resin-coated or uncoated paper. Capture
probe
affixed to polymeric particles can also be immobilized on such flat supports
in a
suitable manner, for example, as dried deposits, or adhered by heat fusion or
with
adhesives. Other details of such materials are provided in EP-A-0 408 738
(published January 23, 1991), WO 92/16659 (published October 1, 1992) and US-
A-5,173,260 (Sutton et al).
The capture probes can be arranged on a suitable support in any
configuration, for example rows of round deposits or stripes.
The following examples are included to illustrate the practice of this
invention, and are not meant to be limiting in any way. All percentages are by
weight unless otherwise noted.
_2152301
-21-
Ma e*-iais and Methods for Examples:
The primers used in the Examples had the
following sequences. The first two are complementary
to the gag region of HIV-I DNA, and the second two
primers are complementary to P-globin DNA.
SEQ ID NO:1: 5'-X-ATAATCCACC TATCCCAGTA GGAGAAAT-3'
SEQ ID NO:2: 5'-X-TTTGGTCCTT GTCTTATGTC CAGAATGC-3'
SEQ ID NO:3: 5'-X-CAACTTCATC CACGTTCACC-3'
SEQ ID NO:4: 5'-ACACAACTGT GTTCACTAGC-31.
In the primers, X represents a biotinyl
moiety (derived from a biotin phosphoramidite
reagent, DuPont) appended to the oligonucleotide
through two aminotetraethylene glycol spacer groups
using the technology described in US-A-4,962,029
(Levenson et al).
The capture probes used in the Examples had
the following sequences, the first being for HIV-I
and the second for 0-globin DNA:
SEQ ID NO:5: 5'-ATCC'PGGGAT TAAATAAAAT AGTAAGAATG
TATAGCCCTA C-Y-3'
SEQ ID NO:6: 51-CCTCAAACAG ACACCATGGT GCACCTGACT
C-Y-3'
"Y" represents two tetraethylene glycol
spacers connected to a single aminediol linking group
using the teaching of US-A-4,914,210 (Levenson et
al).
The primers and capture probes were
prepared using known starting materials and
procedures using an Applied Biosystems Model 380B,
three column DNA synthesizer, standard
phosphoramidite chemistry and the ABI 1 molar scale,
fast cycle protocol. Nucleoside-3'-phosphoramidites
and nucleoside derivatized controlled pore glass
supports were obtained from Applied Biosystems. All
purifications were carried out using a nucleic acid
CA 02152301 2005-08-23
-22-
purification column, followed by reversed phase HPLC techniques.
To form capture reagents, the probes were covalently attached to
polymeric particles (I m average diameter) prepared, using conventional
emulsion
polymerization techniques, from poly[styrene-co-3-(p-vinylbenzylthio)propionic
acid] (95:5 weight ratio, I gm average diameter). A suspension of the
particles in
water was washed with 2-(N-morpholino)ethanesulfonic acid buffer (0.1 molar,
pH
6), and suspended to about 10% solids. A sample (3.3 ml) of the washed
particles,
diluted to 3.33% solids in the buffer (0.1 molar, was mixed with 1-(3-
dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (2.1 ml of 84 mg/mi
water) and the probe (983 l of 44.44 OD/mi nanopure water). The resulting
suspension was heated at 50 C in a water bath for about two hours with
intermittent
mixing and centrifuged. The particles were then washed three times with
tris(hydroxymethyl)aminomethane buffer (0.01 molar, pH 8) containing
(ethylenedinitrilo)tetraacetic acid disodium salt (0.0001 molar) and
resuspended
therein to 4% solids.
Upon dilution to 0.25% solids with buffer, the capture reagents (1.2
gl) were applied to and dried in defined regions of the microporous membranes
(LOPRODYNETM polyamide membrane, 5 m average pore size, from Pall Corp.)
in the test wells of SURECELLTM disposable test devices (available from
Eastman
Kodak Company), which are described in detail in US-A-4,948,561 (Hinckley et
al).
PCR was carried out using an automated Kodak PCR processor which
is described in detail in US-A-5,089,233,
2152301
-23-
using the heating and cooling protocol described in
the Examples below.
Recombinant DNA polymerase from Thermus
aquaticus was obtained using conventional procedures.
Glycerol, tris(hydroxymethyl)aminomethane
buffer and the dNTP's were obtained from Sigma
Chemical.
Low copy target HIV-I DNA was extracted
from the 8E5/LAV cell line using conventional
procedures. Following cell lysis and protein
digestion, the DNA was purified by phenol/chloroform
extraction: tris-saturated phenol (750 l) was added
to the cell suspension, and phenol/lysate solutions
were mixed and separated by centrifugation. The
aqueous phase was then transferred into a fresh 2 ml
tube. This procedure was repeated using chloroform
isoamyl alcohol. The aqueous layer was brought to
0.3 molar sodium acetate. Nucleic acids were
precipitated by adding 95% cold ethanol and storing
at -70 C for 1 hour. The concentration of HIV-I DNA
was then determined at A260 and serial dilutions of
varying copy number were made in TE buffer
[tris(hydroxymethyl)aminomethane (1 mmolar) and
(ethylenedinitrilo)tetraacetic acid (0.1 mmolar)) for
experimental use.
The high copy 0-globin DNA was obtained in
human placental DNA (0.5 mg/ml) which is assumed to
have two copies of the P-globin gene per cell.
The leuco dye dispersion contained agarose
(0.5%), 4,5-bis(4-di~:ethylaminophenyl)-2-(4-hydroxy-
3-methoxyphenyl)imidazole leuco dye (250 molar),
diethylenetriaminepentaacetic acid (100 molar), 4'-
hydroxyacetanilide (5 mmolar), polyvinylpyrrolidone
(112 mmolar) and sod;um phosphate, monobasic, 1-
hydrate (10 mmolar).
CA 02152301 2005-08-23
-24-
The conjugate solution used in the Examples contained a conjugate (126
l/l) of streptavidin and horseradish peroxidase obtained from commercial
sources
(Zymed Laboratories, Inc.), casein (0.5%) and merthiolate (0.5%) in phosphate
buffered saline solution (24 mmolar sodium phosphate and 75 mmolar sodium
chloride). The final conjugate concentration was 312 ng/ml.
The wash solution used in the Examples contained sodium chloride (373
mmolar), (ethylenedinitrilo)tetraacetic acid disodium salt (2.5 mmolar), decyl
sodium
sulfate (38 mmolar) and ethylmercurithiosalicylic acid, sodium salt (25
molar) in
sodium phosphate, monobasic 1-hydrate buffer (25 mmolar, pH 7.4).
The "TP4" monoclonal antibody was used in the reaction mixture. This
antibody is specific to DNA polymerase from Thermus aquaticus and is described
in
more detail in recently allowed U.S. Patent No. 5,338,671 (noted above).
The polymerase chain reaction mixture (100 ml) contained
tris(hydroxymethyl)aminomethane buffer (10 mmolar, pH 8), potassium chloride
(50
mmolar), magnesium chloride (10 mmolar), dATP, dCTP, dGTP and dTTP (1.5 molar
of each), primers (either 0.4 or 1 molar of each), gelatin (0.01%), the noted
DNA
polymerase (either 4 or 16 units/100 l) and the "TP4" monoclonal antibody
(50:1
molar ratio to DNA polymerase).
The remainder of the reagents and materials were obtained using
commercial sources or prepared at Eastman Kodak Company using conventional
procedures.
Examples 1 & 2 Detection of Amplified HIV-I DNA
These examples demonstrate the present invention to coamplify and
detect a low copy target
.2152301
-25-
nucleic acid, HIV-I DNA, in the presence of a high
copy target nucleic acid, (3-globin DNA.
The PCR reaction mixture described above
contained either 5 or 10 copies of HIV-I DNA,-about 1
million copies of (3-globin DNA, and various amounts of
DNA polymerase and primers (0.4 or 1 molar for each
primer of each primer set).
A Control PCR protocol included 40
amplification cycles, each cycle of:
1) heating at 95 C for 15 seconds for
denaturation (195 seconds on first cycle only), and
2) priming (annealing) and extension at
64 C for 30 seconds.
The PCR protocol of this invention
included:
I) 25 primary amplification cycles, each cycle
of:
A) heating at 95 C for 15 seconds for
denaturation (195 seconds on first cycle only), and
B,C) priming (annealing) and extension at
64 C for 30 seconds, and
II) 15 secondary amplification cycles, each
cycle of:
A) heating at 95 C for 15 seconds for
denaturation,
A') renaturation at 75 C for 15 seconds
(Example 1) or 30 seconds (Example 2), and
B,C) priming (annealing) and extension at
64 C for 30 seconds.
The first set of assays were carried out
using 16 units of DNA polymerase/100 l and 10 copies
of HIV-I DNA in the reaction mixture. The second set
of assays were carried out using 4 units of DNA
polymerase/100 l and 5 copies of HIV-I DNA in the
reaction mixture. -
2152301
-26-
Detection of the amplification products was
accomplished in the following manner. A portion (5
l) of the final amplification reaction mixture was
mixed with a buffer solution [tris(hydroxymethyl)-
aminomethane (10 mmolar, pH 8), potassium chloride
(50 mmolar), magnesium chloride (10 mmolar) and
gelatin (0.01%)] (95 l) and incubated at 95 C for 5
minutes to denature the nucleic acids. The resulting
solution was then transferred to SURECELLTM test
devices so amplified target nucleic acids could be
hybridized to the capture probes at 50 C.
The test wells of the test devices were
then washed at 55 C with a buffer solution [sodium
dihydrogen phosphate (10 mmolar), sodium chloride
(150 mmolar), sodium decyl sulfate (1%) and
ethylenediaminetetraacetic acid (1 mmolar)] (250 l,
pH 7.4). The streptavidin-peroxidase conjugate
solution (50 l) noted above was added to each test
well and allowed to flow through the membrane at roor,
temperature. After two minutes, the test wells were
washed a second time.
The leuco dye dispersion (100 l) noted
above was added to each test well, and the devices
were incubated at room temperature for two minutes.
A solution (100 l) of sodium azide (0.1%) was added
to stop dye development.
The resulting dye signals observed in the
assays were visually graded on a density scale of 0
to 10 (highest density). The results of the assays
are shown in Tables I and II below [Table I for the
first set of assays (high DNA polymerase, 10 copies
of HIV-I DNA), and Table II for the second set of
assays (lower DNA polymerase, 5 copies of HIV-I
DNA ) ] .
2152301
-27-
As noted above, Example 1 included a 15
second renaturation step, while Example 2 included a
30 second renaturation step. The Control assay
included no renaturation step.
Table I
Primer Level (Pmolar) PCR Protocol Dye Signal
0.4 Control 6.00
1 Control 4.00
0.4 Example 1 6.75
1 Example 1 7.50
0.4 Example 2 8.00
1 Example 2 8.00
Table II
Primer Level (umolar) PCR Protocol Dye Signal
0.4 Control 2.50
1 Control 0.38
0.4 Example 2 4.75
1 Example 2 3.00
It can be seen from these results that
inclusion of a product renaturation step in the later
cycles of PCR increases the signal obtained from
amplification of the low copy target nucleic acid.
This improvement was observed for both levels of DNA
polymerase and primers used in the assays.
The invention has been described in detail
with particular reference to preferred embodiments-
thereof, but it will be understood that variations and
modifications can be effected within the spirit and
scope of the invention.
21523~~
~..
-28-
SEOLTENCE LISTING
(1) GENERAL INFORMATION
(i) APPLICANT: JOHN W. BACKUS
JOHN W. H. SUTHERLAND
(ii) TITLE: METHOD OF AMPLIFICATION USING
INTERMEDIATE RENATURATION STEP
(iii) NUMBER OF SEQUENCES: 6
(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Eastman Kodak Company,
, Patent Legal Staff
(B) STREET: 343 State Street
(C) CITY: Rochester
(D) STATE: New York
(E) COUNTRY: U.S.A.
(F) ZIP: 14650-2201
(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Diskette, 3.5 inch,
1.44 MB storage (IBM)
(B) COMPUTER: IBM PS/2
(C) OPERATING SYSTEM: MS-DOS Version
3.3
(D) SOFTWARE: PC-8 (Word for Windows
2.0)
(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: To be assigned
(B) FILING DATE: To be assigned
(C) CLASSIFICATION: To be assigned
(vii) PRIOR APPLICATION DATA:
(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Tucker, J. Lanny
(B) REGISTRATION NUMBER: 27,678
(C) REFERENCE/DOCKET NUMBER: 68697
(ix) TELECOMMUNICATION INFORM.ATION:
(A) TELEPHONE: (716) 722-9332
(B) TELEFAX: (716) 477-4646
2152301
-29-
(2) INFORMATION FOR SEQ ID NO: 1
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28
(B) TYPE: Nucleic Acid
(C) STRANDEDNESS: Single
(D) TOPOLOGY: Linear
(ii) MOLECULE TYPE:Primer for HIV-I DNA
(iii) HYPOTHETICAL: No
(iv) ANTI-SENSE: No
(vi) ORIGINAL SOURCE: Synthetically prepared
(vii) IMMEDIATE SOURCE: Same
(x) PUBLICATION INFORMATION: US-A-5,147,777
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1
ATAATCCACC TATCCCAGTA GGAGAAAT 28
(3) INFORMATION FOR SEQ ID NO: 2
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28
(B) TYPE: Nucleic acid
(C) STRANDEDNESS: Single
(D) TOPOLOGY: Linear
(ii) MOLECULE TYPE: Primer for HIV-I DNA
(iii) HYPOTHETICAL: No
(iv) ANTI-SENSE: No
(vi) ORIGINAL SOURCE: Synthetically prepared
(vii) IMMEDIATE SOURCE: Same
(x) PUBLICATION INFORMATION: US-A-5,147,777
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2
TTTGGTCCTT GTCTTATGTC CAGAATGC 28
2152301
-30-
(4) INFORMATION FOR SEQ ID NO: 3
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20
(B) TYPE: Nucleic acid -
(C) STRANDEDNESS: Single
(D) TOPOLOGY: Linear
(ii) MOLECULE TYPE: Primer for 0-globin DNA
(iii) HYPOTHETICAL: No
(iv) ANTI-SENSE: No
(vi) ORIGINAL SOURCE: Synthetically prepared
(vii) IMMEDIATE SOURCE: Same
(x) PUBLICATION INFORMATION: US-A-5,147,777
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3
CAACTTCATC CACGTTCACC 20
(5) INFORMATION FOR SEQ ID NO: 4
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20
(B) TYPE: Nucleic acid
(C) STRANDEDNESS: Single
(D) TOPOLOGY: Linear
(ii) MOLECULE TYPE: Primer for (3-globin DNA
(iii) HYPOTHETICAL: No
(iv) ANTI-SENSE: No
(vi) ORIGINAL SOURCE: Synthetically prepared
(vii) IMMEDIATE SOURCE: Same
(x) PUBLICATION INFORMATION: US-A-5,147,777
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4
ACACAACTGT GTTCACTAGC 20
2152301
-31-
(6) INFORMATION FOR SEQ ID NO: 5
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 41
(B) TYPE: Nucleic acid
(C) STRANDEDNESS: Single
(D) TOPOLOGY: Linear
(ii) MOLECULE TYPE: Probe for HIV-I DNA
(iii) HYPOTHETICAL: No
(iv) ANTI-SENSE: No
(vi) ORIGINAL SOURCE: Synthetically prepared
(vii) IMMEDIATE SOURCE: Same
(x) PUBLICATION INFORMATION: US-A-5,147,777
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5
ATCCTGGGAT TAAATAAAAT AGTAAGAATG TATAGCCCTA C 41
(7) INFORMATION FOR SEQ ID NO: 6
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31
(B) TYPE: Nucleic acid
(C) STRANDEDNESS: Single
(D) TOPOLOGY: Linear
(ii) MOLECULE TYPE: Probe for 0-globin DNA
(iii) HYPOTHETICAL: No
(iv) ANTI-SENSE: No
(vi) ORIGINAL SOURCE: Synthetically prepared
(vii) IMMEDIATE SOURCE: Same
(x) PUBLICATION INFORMATION: US-A-5,147,777
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6
CCTCAAACAG ACACCATGGT GCACCTGACT C 31
